CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 治疗癌症：前景与挑战
英文原题：CAR-T treatment for cancer: prospects and challenges.
查看英文原题
CAR-T treatment for cancer: prospects and challenges.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法已广泛用于血液系统恶性肿瘤并取得显著疗效，但其治疗实体瘤的长期效果受到肿瘤微环境（TME）等因素的严重限制。本文讨论CAR-T 细胞癌症免疫治疗的最新研究和未来展望，比较传统免疫疗法与CAR-T 细胞疗法的不同特点，介绍CAR-T 细胞免疫治疗的最新进展，并分析限制其疗效的障碍，包括免疫抑制因素、代谢能量不足和物理屏障。随后，我们进一步讨论克服这些障碍的最新治疗策略，以及CAR-T 疗法潜在安全问题的管理决策，以推动解决CAR-T 免疫治疗应用受限的问题。
展开英文摘要原文
Chimeric antigen receptor (CAR-T) cell therapy has been widely used in hematological malignancies and has achieved remarkable results, but its long-term efficacy in solid tumors is greatly limited by factors such as the tumor microenvironment (TME).
In this paper, we discuss the latest research and future views on CAR-T cell cancer immunotherapy, compare the different characteristics of traditional immunotherapy and CAR-T cell therapy, introduce the latest progress in CAR-T cell immunotherapy, and analyze the obstacles that hinder the efficacy of CAR-T cell therapy, including immunosuppressive factors, metabolic energy deficiency, and physical barriers.
We then further discuss the latest therapeutic strategies to overcome these barriers, as well as management decisions regarding the possible safety issues of CAR-T cell therapy, to facilitate solutions to the limited use of CAR-T immunotherapy.
论文信息
- 作者
- Chen R、Chen L、Wang C、Zhu H、Gu L、Li Y、Xiong X、Chen G
- 单位
- Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in oncology2023
- 原文标识
- PubMed 38115906 · DOI 10.3389/fonc.2023.1288383
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →